Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-03-21Clinical Trial Update: CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating CAR T cell receptor immunotherapy for B-cell lymphomas completed with posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-27Clinical Trial Update: Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating memory-enriched CAR-T cell therapy for various recurrent B cell lymphomas, including diffuse large B c…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Study of LY2835219 for Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for LY2835219 in mantle cell lymphoma has completed; results posted in 2019.
-
CLINICAL_TRIALS research · 2019-02-01Clinical Trial Update: A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL [Phase 1]
Phase I trial evaluating AC0010 in patients with CLL/SLL, mantle cell lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas [Phase 1]
Phase 1 study of alisertib plus romidepsin in relapsed or refractory B-cell and T-cell lymphomas has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-12-26Clinical Trial Update: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma [Phase 2]
Phase 2 trial assessing maintenance rituximab combined with mTOR inhibition after high-dose consolidative therapy in various B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 2]
Phase 2 trial update examining combination chemotherapy for newly diagnosed mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2018-10-31Clinical Trial Update: Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma [Phase 2, Phase 3]
Phase II/III randomized study evaluating fludarabine/cyclophosphamide with or without rituximab in untreated mantle cell lymphoma has comple…
-
CLINICAL_TRIALS trial_result · 2018-10-19Clinical Trial Update: An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma [Phase 2]
This open-label Phase 2 trial evaluates acalabrutinib (ACP-196) in patients with mantle cell lymphoma, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-28Clinical Trial Update: Safety and Efficacy of BKM120 in Relapsed and Refractory NHL [Phase 2]
Phase 2 trial updating safety and efficacy of BKM120 in relapsed/refractory non-Hodgkin lymphomas (diffuse large B-cell, mantle cell, and fo…
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating a radiolabeled monoclonal antibody with combination chemotherapy before stem cell transplant in high-ris…
-
CLINICAL_TRIALS trial_result · 2018-08-23Clinical Trial Update: Lenalidomide and R-CHOP in B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating the combination of lenalidomide with R-CHOP in various B-cell lymphomas; study completed.
-
CLINICAL_TRIALS trial_result · 2018-08-07Clinical Trial Update: Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial of bortezomib plus vorinostat in recurrent mantle cell lymphoma or recurrent/diffuse large B-cell lymphoma has completed with …
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 study evaluating adding bortezomib after combination chemotherapy, Rituximab, and autologous stem cell transplant in mantle cell lym…
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL [Phase 2]
Phase 2 trial evaluating belinostat combined with Yttrium-90 ibritumomab tiuxetan in relapsed aggressive B-cell non-Hodgkin lymphoma has com…
-
CLINICAL_TRIALS trial_result · 2018-07-26Clinical Trial Update: VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating VELCADE (bortezomib) with BEAM conditioning and autologous stem cell transplantation in non-Hodgkin's lymphoma an…
-
CLINICAL_TRIALS trial_result · 2018-07-03Clinical Trial Update: EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating EPOCH-R chemotherapy plus bortezomib for mantle cell lymphoma has completed, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-07-02Clinical Trial Update: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating a triple regimen of devimistat (CPI-613), bendamustine hydrochloride, and rituximab in relapsed or refractory B-cel…
-
CLINICAL_TRIALS trial_result · 2018-06-26Clinical Trial Update: An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma [Phase 2]
A Phase 2 proof-of-concept study evaluated daratumumab in relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and folli…
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating alisertib with or without rituximab in relapsed or refractory B-cell non-Hodgkin lymphomas was terminated; results …
-
CLINICAL_TRIALS trial_result · 2018-04-30Clinical Trial Update: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients [Phase 2]
Phase 2 trial evaluating a three-drug regimen (Tacrolimus, Bortezomib, and Thymoglobulin) to prevent low-toxicity graft-versus-host disease …
-
CLINICAL_TRIALS trial_result · 2018-04-27Clinical Trial Update: Mantel Cell Lymphoma Efficacy of Rituximab Maintenance [Phase 3]
A Phase 3 trial evaluating rituximab maintenance in mantle cell lymphoma has completed, with results on its efficacy reported in this update…
-
CLINICAL_TRIALS trial_result · 2018-04-19Clinical Trial Update: Safety Study of SGN-CD70A in Cancer Patients [Phase 1]
A Phase 1 safety study of SGN-CD70A in renal cell carcinoma and several lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-12Clinical Trial Update: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers [Phase 3]
Phase 3 trial update on the efficacy and safety of ibrutinib in patients with chronic lymphocytic leukemia and indolent B-cell lymphomas who…
-
CLINICAL_TRIALS trial_result · 2018-03-27Clinical Trial Update: Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study of alisertib (MLN8237) in adults with aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle ce…